The development of new drugs effective against human viral diseases has proven to be both difficult and time-consuming. Indeed, there are but 10 drugs licensed for such applications in the United States today. An attractive solution to this problem may be to optimize the efficacy and selectivity of existing antiviral drugs by combining them with agents that strategically block carefully selected metabolic pathways. This approach was used in the rational design of a three-drug combination to increase the apparent potency of acyclovir against herpes simplex virus. Recent advances in analytical techniques have made the evaluation of this complex drug strategy both possible and practical. A modified version of a previously described analytical method was used to identify optimal drug concentrations and to quantitate statistically significant synergy. Concentrations of 0.25 ,M 5-fluorodeoxyuridine, 3.6 ,uM 2-acetlpyridine thiosemicarbazone, and 0.3 ,uM acyclovir were determined to be optimal in terms of antiviral activity. The volume of synergy produced was nearly 2,000 ,uM3% at a 95% level of confidence (corresponding to a 186-fold decrease in the apparent 50%o inhibitory concentration of acyclovir with the addition of 0.25 ,uM 5-fluorodeoxyuridine and 3.6 ,uM 2-acetylpyridine thiosemicarbazone). We anticipate that this strategic approach and the supporting three-dimensional analytical method will prove valuable in designing and understanding multidrug therapies.
Antiviral drugs derive their specificity through the preferential inhibition of virus-encoded enzymes present in infected cells (13) . The usefulness of these agents is limited by the degree to which they concomitantly affect uninfected cells, producing untoward toxicity. Additionally, the emergence of drug-resistant mutants is a significant problem in single-drug therapy (3) . Treatment with combinations of antiviral agents is generally thought to minimize drug resistance (1, 6, 14) but may or may not offer increased selectivity and efficacy. Traditionally, drug combinations have been chosen on the basis of the potency and/or efficacy of the individual agents. The component drugs often have been active against the same target, and detailed evaluations of drug interactions often have been lacking. Combiwitions of drugs that inhibit different targets, however, often offer surprising potency, even though one or more of the constituent c6mpounds may be weakly active. We now describe the rational design of an antiviral combination of three drugs that strategically inhibits the replication of herpes simplex virus (HSV) by blocking carefully chosen metabolic pathways. Evaluation of this strategy and the determination of optimal drug concentrations were made possible by recent advances in existing three-dimensional analytical procedures (21, 22) .
The rational design of a combination of drugs relies on a thorough understanding of drug metabolism in both virusinfected and uninfected cells. The antiherpesvirus drug acyclovir (ACV; Zovirax) is a potent inhibitor of HSV replication and is an apparent inactivator of the HSV DNA polymerase (5) . This drug is initially phosphorylated by the HSV pyrimidine deoxyribonucleoside kinase and is further phosphorylated by cellular kinases to ACV triphosphate (ACVTP) (Fig. 1) , the active form of the drug (25) .
In HSV-infected cells, ACV limits its own effectiveness on at least two levels. Treatment with ACV results in an increase in both thymidylate synthase activity and the size of intracellular thymidine pools (11) . Thymidine competes with ACV for phosphorylation by the HSV pyrimidine deoxyribonucleoside kinase (TK) (9) . This alteration of nucleoside metabolism adversely affects the efficiency with which ACV can inhibit the HSV DNA polymerase, as less ACV is phosphorylated (Fig. 1) . ACV also significantly increases the size of deoxyribonucleoside triphosphate (dNTP) pools, including dGTP (7, 11) . Thus, the effectiveness of ACV is further limited, as dGTP competes with ACVTP for binding by the HSV DNA polymerase (Fig. 1) . ACV increases the sizes of both thymidine and dGTP pools. Thus, for optimization of the antiviral activity of ACV, it would be desirable to decrease the sizes of both the pyrimidine deoxyribonucleoside pools and the dGTP pools in infected cells. This strategy would remove molecules that compete with ACV for both activation and incorporation, theoretically resulting in increased phosphorylation of ACV to its active form and maximizing the incorporation of ACVTP by the HSV DNA polymerase. The predicted result of this increased activation and incorporation would be synergistic inhibition of viral replication by drugs that decrease the size of either thymidine (dThd) or dGTP pools. This strategy also predicts that even more synergy would be produced by a combination of inhibitors that simultaneously decrease the sizes of both dThd and dGTP pools.
Early experiments by Cohen demonstrated that HSV stimulated the synthesis of DNA in thymidine-blocked cells (4) . Cohen and coworkers later demonstrated that this effect was due primarily to the expression of a viral ribonucleoside diphosphate reductase (ribonucleotide reductase; RR) (18) . We have shown that HSV type 1 (HSV-1) requires this increased synthesis of deoxynucleotides to replicate efficiently (22a). Inhibitors of the RR have been shown to potentiate the antiviral effects of ACV (21, (29) (30) (31) (32, 33) and is also a potent inhibitor of HSV both in vitro and in vivo (27, 28 (10) . Previous experiments in our laboratory showed that this drug also potentiates the antiviral effects of ACV (20) . Thus, we predicted that the three-drug combination of ACV, APTS, and 5-FdUrd should act in a synergistic manner to inhibit the replication of HSV. Furthermore, the three-drug combination should produce more synergy than any of the three possible two-drug combinations.
MATERIALS AND METHODS

Chemicals. APTS was prepared by Derse and Schroeder
Associates, Ltd., Madison, Wis. ACV was provided through the courtesy of Sandra Lehrman of the Burroughs Wellcome Co., Research Triangle Park, N.C. 5-FdUrd was obtained from Sigma Chemical Co., St. Louis, Mo., and KH2PO4 was obtained from ICN Biomedicals Inc., Costa Mesa, Calif.
Cell line and virus. BS-C-1 cells, an established line of African green monkey kidney cells, were grown in monolayers in minimal essential medium with Earle salts and supplemented with 10% calf serum as described previously (23) . Cells were routinely passaged with 0.05% trypsin-0.02% EDTA in N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES)-buffered saline (HBS) (26) . The KOS strain of HSV-1 was obtained from Sandra Weller of the University of Connecticut, Farmington. The virus was grown and its titers were determined as described previously (23) .
dNTP pool size determinations. Exponentially growing BS-C-1 cells were passaged 12 h prior to infection and/or drug treatment. The cell sheets, containing 3 x 106 to 6 x 106 exponentially growing BS-C-1 cells, were infected at a multiplicity of infection of 10 with HSV-1 (strain KOS). The medium was replaced, and drugs were added after a 1-h adsorption period. At 6 h postinfection, the cells were washed twice with HBS at 37°C and trypsinized as described above. The extraction protocol is based on the procedure described by Garret and Santi (8 Since three drugs were used in this experiment, the existing software was modified to accommodate the expanded experimental design. Furthermore, additive drug interactions were calculated with the following equation:
.I=1-f| (l-in) (1) n=1 where I is the predicted fractional inhibition produced by the combination and i is the fractional inhibition produced by n drugs used individually. Equation 1 is the general form of equation 2, which is the dissimilar-site additivity equation described previously (21, 22) :
where Z represents the total inhibition produced by the combination of drugs X and Y and X and Y represent the inhibition produced by drugs X and Y alone, respectively. Both equations 1 and 2 correspond to the independenteffects equations used by some investigators (16, 17, 34) .
The results presented here were based on data from checkerboard dilution matrices, which included the drugs used individually (21, 22) . This experimental design was used to identify regions at which significant drug interactions occurred (19 (12) (13) (14) .
Cytotoxicity determinations. Simultaneous cytotoxicity control experiments were done as described above, except that the plates were not infected with virus. The evaluation of cytotoxicity was based on a procedure described previously (19) . In brief, cell growth was quantitated by staining the cell sheets with crystal violet and measuring the bound dye by elution with 1% (vol/vol) HCl in ethanol. The optical density was determined at 570 and 405 nm in a Microplate Bio-Kinetics Reader.
RESULTS
To test the strategically designed drug cor-4"9ation, we measured the antiviral effect of the three-drn_.nbination and experimentally determined the optimal coincentrations of each drug. Data were generated by use of an EIA with horseradish peroxidase-conjugated polyclonal antibodies to HSV-1. With this technique, the replication of HSV-1 (strain KOS) was measured in triplicate at 300 different combinations of concentrations of the three drugs. The data were analyzed as described above and plotted as a vertical series of contour plots (Fig. 2) .
Synergistic antiviral interactions between APTS and ACV are shown in the bottom tier of The addition of 0.25 p.M 5-FdUrd dramatically increased the volume of synergy to 602 p.M2% (Fig. 2, second tier) , more than fivefold higher than that observed with the combination of ACV and APTS alone (Fig. 2, bottom tier) . As the concentrations of 5-FdUrd were increased, synergy among the three drugs decreased because of the antiviral activity of 5-FdUrd. The optimal combination of ACV, APTS, and 5-FdUrd was at a molar ratio of approximately 2:14: 1. The volume of synergy produced by the three-drug combination was 1,988 ,uM3%. This value corresponded to a 186-fold decrease in the apparent 50% inhibitory concentration of ACV with the addition of 3.6 p.M APTS and 0.25 p.M 5-FdUrd. Calculations revealed that the volume of synergy produced by the three-drug combination was larger than expected on the basis of the synergy produced by the synergistic two-drug combinations (APTS and ACV; 5-FdUrd and ACV). It is clear that the three-drug combination inhibited the replication of HSV-1 better than any drug by itself or any two-drug combination.
We have shown that the three-drug combination is highly efficacious in inhibiting the replication of HSV-1. It is equally important, however, to evaluate any combination of drugs for potential synergistic cytotoxicity. The cytotoxicity of the three-drug combination was evaluated in BS-C-1 cells by a cytotoxicity assay described previously (19) and analyzed by the three-dimensional dose-response method described above. No significant synergistic cytotoxicity or antagonism of cytotoxicity was observed in any of the regions of Fig. 2 (data not shown). Thus, we concluded that the effects seen in Fig. 2 were not due to synergistic cytotoxicity and that the toxicity of the three-drug combination was additive.
To confirm the mechanism(s) of the observed synergistic effect of the three-drug combination, we measured dNTP pools in HSV-1-infected cells treated with the individual drugs and the three-drug combination at the optimal ratio ( Table 1 ). The results confirm that ACV increased the sizes of all of the dNTP pools, an observation consistent with results published previously (7) . Infected cells treated with APTS had greatly reduced purine deoxyribonucleoside pool sizes as a direct result of the inhibition of the RR. This effect was also seen for infected cells treated with the two-drug combination of ACV and APTS. Here, APTS prevented the increase in the size of dGTP pools, thus increasing the ratio of ACVTP to its competitor dGTP by 20-fold. APTS did not prevent the increase in the size of pools of dTTP or dCTP; this phenomenon, although not understood, has been reported for other inhibitors of the RR, such as hydroxyurea (2) . As predicted, 5-FdUrd decreased the size of dTTP pools in infected cells. The three-drug combination of ACV, APTS, and 5-FdUrd resulted in decreased dTTP and dGTP pool sizes and in a 33-fold increase in the ratio of ACVTP to dGTP.
DISCUSSION
The drug combination presented here was rationally designed to optimize the efficacy of the antiviral drug ACV. Previous studies demonstrated that decreasing dGTP pools with RR inhibitors increases the apparent potency of ACV by increasing the ACVTP/dGTP ratio (29) (30) (31) . Inhibitors of RR, however, are unable to inhibit the increase in the size of pools of pyrimidine deoxyribonucleosides (2) , which reduces the phosphorylation of ACV (9). Our strategy used (i) an inhibitor of the cellular thymidylate synthase to decrease the size of the intracellular dThd pools and (ii) an inhibitor of the HSV RR to decrease the size of the intracellular dGTP pools. As predicted, the combination of APTS, 5-FdUrd, and ACV synergistically inhibited the replication of HSV and was a much more potent combination than ACV and an RR inhibitor alone.
The measurement of intracellular dNTP pool sizes confirmed the proposed mechanism of synergy. In infected cells, 5-FdUrd decreased the sizes of dTTP and dCTP pools but did not eliminate them. Previous experiments by Nutter and coworkers (15) suggested that the large increase in the size of dTTP pools seen in infected cells was due mainly to thymidine salvaged from degraded cellular DNA. Furthermore, these pools appeared to be compartmentalized, as salvaged thymidine not efficiently used for incorporation into viral DNA (15, 22a) . The inability of 5-FdUrd to eliminate dTTP pools in infected cells would appear to confirm that some salvage does occur. We also showed that the inhibition of thymidylate synthase correlated well with the potentiation of ACV (20) . Thus, the small decrease in the size of dTTP pools in infected cells treated with the three-drug combination may reflect the suppression of the small pools of thymidine that are used in the synthesis of viral DNA.
The data presented in this communication describe the rational design and evaluation of a combination of drugs that optimized the efficacy and selectivity of ACV. A novel analytical procedure demonstrated that the three drugs acted cooperatively to inhibit the replication of HSV-1 and identified the optimal concentration of each drug. The apparent potency of ACV could be increased by more than 186-fold without producing synergistic cytotoxicity. We do not endorse this particular drug combination for clinical use because of the toxicity known to be associated with 5-FdUrd. Nevertheless, we have clearly shown that it is possible to rationally design and evaluate efficacious and selective combinations of drugs in vitro. One would hope that this approach would be helpful in predicting the usefulness of combinations of drugs in the treatment of human disease.
